ALB and neoplasm: Patients with poor performance status (ECOG 2 or more), extrahepatic metastases, portal vein thrombosis extending to the main left/right branch, tumor burden > 50% of the liver volume, and a baseline alteration of the liver function (albumin–bilirubin score of 3 or bilirubin level of 2–3 mg/dL) have reported median survival rates that fall between 4.3 and 8.2 mo (Table 6).